Pulmonology Division, College of Public Health, University of São Paulo, São Paulo, Brazil.
Pulmonology Division, College of Public Health, University of São Paulo, São Paulo, Brazil.
Chest. 2013 Sep;144(3):974-980. doi: 10.1378/chest.12-2280.
Patients with postinfectious bronchiolitis obliterans (PIBO) usually have severe airflow obstruction and respond poorly to β-adrenergic drugs. However, the bronchodilator response to an anticholinergic agent such as tiotropium bromide is not known. We studied the acute bronchodilator response to tiotropium for up to 24 h in children with PIBO using spirometric and plethysmographic criteria.
A randomized, double-blind, placebo-controlled, crossover, prospective study was performed in patients with stable PIBO, 6 to 16 years of age. Standard spirometry and plethysmography were performed before and at 30, 60, 120, and 180 min and 24 h after inhalation of 18 μg of tiotropium or a placebo. After 7 to 14 days, the drugs were inverted, and the procedures were repeated. The changes in lung function parameters at each time point were compared with the baseline by analysis of variance and Tukey posttest, and the differences in all time points assessments vs baseline in tiotropium vs placebo groups were compared using the Friedman test.
A total of 30 patients were enrolled in the study (23 boys, seven girls; aged 10.9 ± 2.8 years) with baseline lung function values (% predicted) of FVC, FEV1, FEV1/FVC, forced expiratory flow between 25% and 75% of FVC (FEF25%-75%), total lung capacity (TLC), residual volume (RV), RV/TLC, airway resistance (Raw), and specific airway conductance (sGaw) of 75 ± 15, 48 ± 14, 59 ± 11, 22 ± 11, 120 ± 19, 281 ± 101, 49 ± 13, 250 ± 65, and 23 ± 9, respectively. Statistically significant differences were observed after tiotropium inhalation in the following parameters compared with baseline: FVC at 60, 120, and 180 min and 24 h; FEV1 at 30, 60, 120, and 180 min; FEV1/FVC at 60, 120, and 180 min; FEF25%-75% at 60, 120, and 180 min; RV at 30, 60, 120, and 180 min; TLC at 30, 120, and 180 min; RV/TLC at 30, 60, 120, and 180 min; Raw at 30, 60, 120, and 180 min and 24 h; and sGaw at 30, 60, 120, and 180 min and 24 h. For the placebo group, no significant differences were observed in any lung function parameters at any time. The differences in the main functional measurements between the tiotropium and placebo groups were statistically significant.
Tiotropium acutely decreased airway obstruction and air trapping for up to 24 h in children with PIBO.
患有感染后细支气管炎性气道阻塞(PIBO)的患者通常存在严重的气流阻塞,并且对β-肾上腺素能药物反应不佳。然而,尚不清楚抗胆碱能药物如噻托溴铵对其支气管扩张作用。我们使用肺量计和体描法研究了儿童 PIBO 患者使用噻托溴铵长达 24 小时的急性支气管扩张反应。
对 6 至 16 岁稳定的 PIBO 患者进行了一项随机、双盲、安慰剂对照、交叉、前瞻性研究。在吸入 18μg 噻托溴铵或安慰剂前和吸入后 30、60、120 和 180 分钟以及 24 小时,分别进行标准肺量计和体描法检查。在 7 至 14 天后,颠倒药物并重复该程序。通过方差分析和 Tukey 后测试比较每个时间点的肺功能参数与基线的变化,并使用 Friedman 检验比较噻托溴铵组和安慰剂组在所有时间点评估与基线的差异。
共有 30 名患者入组(23 名男孩,7 名女孩;年龄 10.9 ± 2.8 岁),基线肺功能值(%预测)为 FVC、FEV1、FEV1/FVC、用力呼出 25%至 75%肺活量的流速(FEF25%-75%)、总肺容量(TLC)、残气量(RV)、RV/TLC、气道阻力(Raw)和特异性气道传导率(sGaw)分别为 75 ± 15、48 ± 14、59 ± 11、22 ± 11、120 ± 19、281 ± 101、49 ± 13、250 ± 65 和 23 ± 9。与基线相比,吸入噻托溴铵后以下参数有统计学意义的差异:60、120 和 180 分钟及 24 小时的 FVC;30、60、120 和 180 分钟的 FEV1;60、120 和 180 分钟的 FEV1/FVC;60、120 和 180 分钟的 FEF25%-75%;30、60、120 和 180 分钟的 RV;30、120 和 180 分钟的 TLC;30、60、120 和 180 分钟的 RV/TLC;30、60、120、180 分钟和 24 小时的 Raw;30、60、120、180 分钟和 24 小时的 sGaw。在安慰剂组,任何时间的任何肺功能参数均无显著差异。噻托溴铵组和安慰剂组之间的主要功能测量差异具有统计学意义。
噻托溴铵可急性降低儿童 PIBO 长达 24 小时的气道阻塞和空气滞留。